Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
25 results
D2.182 - Low-dose oral food challenge (OFC) in a pediatric day-care hospital: a pre-immunotherapy approach for managing nut-allergies in children
D2.183 - Assessment of Incidence and Onset of Eosinophilic Esophagitis during the clinical development of Peanut (Arachis hypogaea) Allergen Powder-dried non-fat protein for oral immunotherapy
D2.184 - Trends in aeroallergen immunotherapy prescription
D2.185 - Ultrarush honeybee venom immunotherapy in patients with monoclonal mast cell activation syndrome: two case reports
D2.186 - Toxicity Assessment of Repeated Doses of Apis mellifera Venom for Immunotherapy
D2.187 - Can the Conjunctival Allergen Provocation Test Improve Long-Term Adherence to Subcutaneous Allergen-Specific Immunotherapy?
D2.188 - Low allergenicity of food allergen by Galactomannan Conjugation and immunotherapeutic efficacy of peanut-galactomannan conjugate in a mouse model of peanut allergy
D2.189 - Eosinophilic Esophagitis Induced by Sublingual Immunotherapy (SLIT): A Rare but Emerging Side Effect
D2.190 - Unmasking Autoimmunity: A Case of Thyroiditis Emerging After Allergy Immunotherapy
D2.191 - Autoimmune Disease Unmasked by Allergic Immunotherapy: A Case of Systemic Lupus Erythematosus (SLE) After SCIT
D2.192 - IgE-Mediated Immunotherapy-Induced Eosinophilic Granulomatosis with Polyangiitis (EGPA)
D2.193 - Oral Induction of Tolerance to Cow's Milk Protein Allergy in Omani Children: A Retrospective Analysis
D2.294 - Allergic contact dermatitis unit at Hospital Joan XXIII (Tarragona, Spain): descriptive analysis 2022 - 2023
D2.295 - Characterization of Treatment-Refractory Chronic Urticaria: A Large-Scale Retrospective Analysis of Clinical and Laboratory Parameters
D2.296 - Allergic contact dermatitis caused by a oxybutynin in a transdermal patch
D2.297 - SEP-631: A Novel Selective and Potent Oral MRGPRX2 Inhibitor for the Treatment of Chronic Spontaneous Urticaria
D2.299 - A novel synthetic molecule LN49 suppressed oxidative stress and inflammation in skin epithelial and fibroblast cells via activating Nrf-2 signaling pathway
D2.300 - Fixed Drug Eruption related to the use of NSAIDs
D2.302 - Non - immediate hypersensitivity to oxybutynin, first confirmed case with lymphocyte transformation test
D2.303 - Blistering Discovery: A Rare Case of Toxic Epidermal Necrolysis Triggered by Carboplatin and Radiotherapy
Pagination
Current page
1
Page
2
Next page
Next
Last page
Last
Download the app
The congress at your fingertips
Available on
Download